Published in Clin Infect Dis on April 01, 2008
Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev (2012) 5.65
Biosynthesis of phosphonic and phosphinic acid natural products. Annu Rev Biochem (2009) 2.19
In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother (2009) 2.12
ESBLs: A Clear and Present Danger? Crit Care Res Pract (2011) 1.77
Dissemination of the fosfomycin resistance gene fosA3 with CTX-M β-lactamase genes and rmtB carried on IncFII plasmids among Escherichia coli isolates from pets in China. Antimicrob Agents Chemother (2012) 1.54
Susceptibility of urinary tract bacteria to fosfomycin. Antimicrob Agents Chemother (2009) 1.38
Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections. Open Forum Infect Dis (2015) 1.34
Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods. Antimicrob Agents Chemother (2011) 1.25
Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin. Eur J Med Res (2010) 1.20
Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother (2014) 1.19
In vitro activity of fosfomycin alone and in combination with ceftriaxone or azithromycin against clinical Neisseria gonorrhoeae isolates. Antimicrob Agents Chemother (2014) 1.05
Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria. Eur J Clin Pharmacol (2010) 1.05
Increasing antimicrobial resistance among uropathogens: Is fosfomycin the answer? Urol Ann (2015) 1.03
'Old' antibiotics for emerging multidrug-resistant bacteria. Curr Opin Infect Dis (2012) 1.02
Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011). Haematologica (2013) 0.99
Different biosynthetic pathways to fosfomycin in Pseudomonas syringae and Streptomyces species. Antimicrob Agents Chemother (2012) 0.98
Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin. Eur J Clin Microbiol Infect Dis (2008) 0.97
High-dose daptomycin and fosfomycin treatment of a patient with endocarditis caused by daptomycin-nonsusceptible Staphylococcus aureus: case report. BMC Infect Dis (2011) 0.95
Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections. PLoS One (2010) 0.95
A new strategy to fight antimicrobial resistance: the revival of old antibiotics. Front Microbiol (2014) 0.94
Diversity of Acinetobacter baumannii in four French military hospitals, as assessed by multiple locus variable number of tandem repeats analysis. PLoS One (2012) 0.93
Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur J Clin Microbiol Infect Dis (2011) 0.93
Daptomycin, fosfomycin, or both for treatment of methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model. Antimicrob Agents Chemother (2011) 0.92
Structural and chemical aspects of resistance to the antibiotic fosfomycin conferred by FosB from Bacillus cereus. Biochemistry (2013) 0.91
A cell wall recycling shortcut that bypasses peptidoglycan de novo biosynthesis. Nat Chem Biol (2013) 0.90
Fosfomycin. Clin Microbiol Rev (2016) 0.89
Determination of Extended-Spectrum β-Lactamases and AmpC Production in Uropathogenic Isolates of Escherichia coli and Susceptibility to Fosfomycin. J Lab Physicians (2013) 0.89
Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply "precision medicine" to antimicrobial chemotherapy? Expert Opin Pharmacother (2016) 0.89
Efficacy of fosfomycin in experimental osteomyelitis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2010) 0.88
Genomewide overexpression screen for fosfomycin resistance in Escherichia coli: MurA confers clinical resistance at low fitness cost. Antimicrob Agents Chemother (2012) 0.88
Fosfomycin in a single dose versus a 7-day course of amoxicillin-clavulanate for the treatment of asymptomatic bacteriuria during pregnancy. Eur J Clin Microbiol Infect Dis (2009) 0.86
Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother (2014) 0.86
Fosfomycin: Resurgence of an old companion. J Infect Chemother (2016) 0.86
Blocking peptidoglycan recycling in Pseudomonas aeruginosa attenuates intrinsic resistance to fosfomycin. Microb Drug Resist (2014) 0.85
Molecular Mechanisms and Clinical Impact of Acquired and Intrinsic Fosfomycin Resistance. Antibiotics (Basel) (2013) 0.85
Structure and function of the genomically encoded fosfomycin resistance enzyme, FosB, from Staphylococcus aureus. Biochemistry (2014) 0.83
Efficacy of fosfomycin compared to vancomycin in treatment of implant-associated chronic methicillin-resistant Staphylococcus aureus osteomyelitis in rats. Antimicrob Agents Chemother (2014) 0.81
Identification of a novel UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) from Vibrio fischeri that confers high fosfomycin resistance in Escherichia coli. Arch Microbiol (2009) 0.81
Susceptibility of multiresistant gram-negative bacteria to fosfomycin and performance of different susceptibility testing methods. Antimicrob Agents Chemother (2013) 0.80
Fosfomycin tromethamine. Antibiotic of choice in the female patient: A multicenter study. Cent European J Urol (2015) 0.80
Structural and biochemical insights into the mechanism of fosfomycin phosphorylation by fosfomycin resistance kinase FomA. Biochemistry (2011) 0.79
Testing the mutant selection window hypothesis in vitro and in vivo with Staphylococcus aureus exposed to fosfomycin. Eur J Clin Microbiol Infect Dis (2014) 0.79
Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database. Infect Dis Ther (2015) 0.78
Antibiotic Resistance of Pseudomonas aeruginosa in Pneumonia at a Single University Hospital Center in Germany over a 10-Year Period. PLoS One (2015) 0.78
Fosfomycin: Uses and potentialities in veterinary medicine. Open Vet J (2014) 0.77
The use of prophylactic single-dose fosfomycin in patients who undergo transrectal ultrasound-guided prostate biopsy: A prospective, randomized, and controlled clinical study. Can Urol Assoc J (2015) 0.77
Fosfomycin: A First-Line Oral Therapy for Acute Uncomplicated Cystitis. Can J Infect Dis Med Microbiol (2016) 0.77
Bacillithiol: a key protective thiol in Staphylococcus aureus. Expert Rev Anti Infect Ther (2015) 0.75
Evaluation of the Effect of Radiofrequency Radiation Emitted From Wi-Fi Router and Mobile Phone Simulator on the Antibacterial Susceptibility of Pathogenic Bacteria Listeria monocytogenes and Escherichia coli. Dose Response (2017) 0.75
Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study. BMC Infect Dis (2016) 0.75
Cefepime shows good efficacy and no antibiotic resistance in pneumonia caused by Serratia marcescens and Proteus mirabilis - an observational study. BMC Pharmacol Toxicol (2016) 0.75
Fosfomycin antimicrobial prophylaxis for transrectal ultrasound-guided biopsy of the prostate: A prospective randomised study. Arab J Urol (2016) 0.75
Successful treatment of a disseminated infection with extensively drug-resistant Klebsiella pneumoniae in a liver transplant recipient with a fosfomycin-based multidrug regimen. Transpl Infect Dis (2016) 0.75
Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study. J Antibiot (Tokyo) (2016) 0.75
Penetration of fosfomycin into IPEC-J2 cells in the presence or absence of deoxynivalenol. PLoS One (2013) 0.75
Is a New Standard Needed for Diffusion Methods for In Vitro Susceptibility Testing of Fosfomycin against Pseudomonas aeruginosa? Antimicrob Agents Chemother (2015) 0.75
Use of linezolid in neonatal and pediatric inpatient facilities--results of a retrospective multicenter survey. Eur J Clin Microbiol Infect Dis (2011) 0.75
Stereoselective epoxidation of cis-propenylphosphonic acid to fosfomycin by a newly isolated bacterium Bacillus simplex strain S101. J Ind Microbiol Biotechnol (2009) 0.75
Fosfomycin induced structural change in fosfomycin resistance kinases FomA: molecular dynamics and molecular docking studies. J Mol Model (2014) 0.75
Pharmacodynamic evaluation of fosfomycin against E. coli and Klebsiella spp. from urinary tract infections and the influence of pH on fosfomycin activities. Antimicrob Agents Chemother (2017) 0.75
Frequency of colistin and fosfomycin resistance in carbapenem-resistant Enterobacteriaceae from a tertiary care hospital in Karachi. Infect Drug Resist (2017) 0.75
Characterization of Extended-Spectrum β-Lactamase Genes of Shigella flexneri Isolates With Fosfomycin Resistance From Patients in China. Ann Lab Med (2017) 0.75
Obesity and infection. Lancet Infect Dis (2006) 2.94
Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence. J Antimicrob Chemother (2007) 2.79
Comparison of SCImago journal rank indicator with journal impact factor. FASEB J (2008) 2.77
Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis (2010) 2.60
Antibiotics versus placebo in the treatment of women with uncomplicated cystitis: a meta-analysis of randomized controlled trials. J Infect (2009) 2.40
The top-ten in journal impact factor manipulation. Arch Immunol Ther Exp (Warsz) (2008) 2.32
Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet (2009) 2.26
Risk factors for mortality in patients with emphysematous pyelonephritis: a meta-analysis. J Urol (2007) 2.09
β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis (2011) 2.03
Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother (2012) 2.01
Informed consent: how much and what do patients understand? Am J Surg (2009) 1.90
Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J Antimicrob Chemother (2007) 1.89
Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents (2009) 1.88
Statins for infection and sepsis: a systematic review of the clinical evidence. J Antimicrob Chemother (2008) 1.85
Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother (2013) 1.85
Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: the study, the patient, the bug or the drug? J Infect (2012) 1.84
Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. J Antimicrob Chemother (2008) 1.73
Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study. Crit Care Med (2008) 1.69
Resistance to polymyxins: Mechanisms, frequency and treatment options. Drug Resist Updat (2010) 1.66
The effect of psychosocial factors on breast cancer outcome: a systematic review. Breast Cancer Res (2007) 1.65
Fluoroquinolones compared with beta-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials. CMAJ (2008) 1.60
Worldwide prevalence of head lice. Emerg Infect Dis (2008) 1.58
Attributable mortality of Acinetobacter baumannii: no longer a controversial issue. Crit Care (2007) 1.52
A bibliometric analysis by geographic area of published research in several biomedical fields, 1995-2003. CMAJ (2006) 1.46
World Wide Web resources on antimicrobial resistance. Clin Infect Dis (2006) 1.46
Microbiologically documented nosocomial infections after coronary artery bypass surgery without cardiopulmonary bypass. J Thorac Cardiovasc Surg (2006) 1.45
World databases of summaries of articles in the biomedical fields. Arch Intern Med (2007) 1.43
Non-physicians may reach correct diagnoses by using Google: a pilot study. Swiss Med Wkly (2008) 1.40
Comparison of mortality of patients with Acinetobacter baumannii bacteraemia receiving appropriate and inappropriate empirical therapy. J Antimicrob Chemother (2006) 1.39
Susceptibility of urinary tract bacteria to fosfomycin. Antimicrob Agents Chemother (2009) 1.38
Tuberculosis of the oral cavity: a systematic review. Eur J Oral Sci (2010) 1.37
Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int J Antimicrob Agents (2008) 1.36
Attributable mortality of Stenotrophomonas maltophilia infections: a systematic review of the literature. Future Microbiol (2009) 1.34
Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents (2012) 1.32
Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents (2009) 1.23
Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies. Expert Opin Investig Drugs (2009) 1.19
Intravenous heparin in combination with antibiotics for the treatment of deep vein septic thrombophlebitis: a systematic review. Eur J Pharmacol (2006) 1.12
Pyomyositis associated with hematological malignancy: case report and review of the literature. Int J Infect Dis (2007) 1.09
Daptomycin for treatment of patients with bone and joint infections: a systematic review of the clinical evidence. Int J Antimicrob Agents (2007) 1.08
Treatment options for 2009 H1N1 influenza: evaluation of the published evidence. Int J Antimicrob Agents (2010) 1.07
Outcome of antimicrobial therapy in documented biofilm-associated infections: a review of the available clinical evidence. Drugs (2009) 1.07
Risk factors for development of Clostridium difficile infection due to BI/NAP1/027 strain: a meta-analysis. Int J Infect Dis (2012) 1.05
Arrhythmias associated with fluoroquinolone therapy. Int J Antimicrob Agents (2007) 1.05
Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria. Eur J Clin Pharmacol (2010) 1.05
Cure of post-traumatic recurrent multiresistant Gram-negative rod meningitis with intraventricular colistin. J Infect (2005) 1.05
Chronic bacterial and parasitic infections and cancer: a review. J Infect Dev Ctries (2010) 1.03
Systemic colistin use in children without cystic fibrosis: a systematic review of the literature. Int J Antimicrob Agents (2009) 1.02
Comparison of antibiotics with placebo for treatment of acute sinusitis: a meta-analysis of randomised controlled trials. Lancet Infect Dis (2008) 1.01
Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence. J Antimicrob Chemother (2007) 0.99
Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother (2010) 0.99
Inhaled colistin as monotherapy for multidrug-resistant gram (-) nosocomial pneumonia: a case series. Respir Med (2008) 0.95
Intravenous colistimethate (colistin) use in critically ill children without cystic fibrosis. Pediatr Infect Dis J (2009) 0.94
Current diagnosis and management of infectious mononucleosis. Curr Opin Hematol (2012) 0.93
Do PubMed and Google searches help medical students and young doctors reach the correct diagnosis? A pilot study. Eur J Intern Med (2009) 0.93
Comparison of utility of blood cultures from intravascular catheters and peripheral veins: a systematic review and decision analysis. J Med Microbiol (2008) 0.93
Case 38-2013: A man with fever and lymphadenopathy. N Engl J Med (2014) 0.92
Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis. PLoS One (2012) 0.91
Antimicrobial susceptibility of Gram-negative nonurinary bacteria to fosfomycin and other antimicrobials. Future Microbiol (2010) 0.91
Bacterial interference for the prevention and treatment of infections. Int J Antimicrob Agents (2008) 0.90
Impact of vancomycin minimum inhibitory concentration on clinical outcomes of patients with vancomycin-susceptible Staphylococcus aureus infections: a meta-analysis and meta-regression. Int J Antimicrob Agents (2012) 0.90
Increasing contribution of China in modern biomedical research. Statistical data from ISI Web of Knowledge. Med Sci Monit (2009) 0.90
Patients' perception of quality of pre-operative informed consent in athens, Greece: a pilot study. PLoS One (2009) 0.90
Treatment of viral conjunctivitis with antiviral drugs. Drugs (2011) 0.89
Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: a meta-analysis of randomized controlled trials. J Antimicrob Chemother (2010) 0.87
Safety of hepatitis B, pneumococcal polysaccharide and meningococcal polysaccharide vaccines in pregnancy: a systematic review. Drug Saf (2012) 0.87
Candida albicans versus non-albicans bloodstream infection in patients in a tertiary hospital: an analysis of microbiological data. Scand J Infect Dis (2008) 0.87
Antimicrobial resistance of Esherichia coli urinary isolates from primary care patients in Greece. Med Sci Monit (2008) 0.87
Re-emergence of colistin in today's world of multidrug-resistant organisms: personal perspectives. Expert Opin Investig Drugs (2008) 0.86
Impact of antibiotic MIC on infection outcome in patients with susceptible Gram-negative bacteria: a systematic review and meta-analysis. Antimicrob Agents Chemother (2012) 0.85
When to include polymyxins in the empirical antibiotic regimen in critically ill patients with fever? A decision analysis approach. Shock (2007) 0.85
Nephrotoxicity of colistin: new insight into an old antibiotic. Clin Infect Dis (2009) 0.85
Secular trends of antimicrobial resistance of blood isolates in a newly founded Greek hospital. BMC Infect Dis (2006) 0.84
Frequency of the off-label use of antibiotics in clinical practice: a systematic review. Expert Rev Anti Infect Ther (2012) 0.83
Study of the topographic distribution of ets-1 protein expression in invasive breast carcinomas in relation to tumor phenotype. Cancer Detect Prev (2006) 0.83
Effectiveness and safety of tigecycline: focus on use for approved indications. Clin Infect Dis (2012) 0.82
Seasonality of mortality: the September phenomenon in Mediterranean countries. CMAJ (2009) 0.82
Susceptibility of Gram-negative bacteria to isepamicin: a systematic review. Expert Rev Anti Infect Ther (2012) 0.81
Early switch to oral versus intravenous antimicrobial treatment for hospitalized patients with acute pyelonephritis: a systematic review of randomized controlled trials. Curr Med Res Opin (2008) 0.81
Once versus multiple daily dosing of aminoglycosides for patients with febrile neutropenia: a systematic review and meta-analysis. J Antimicrob Chemother (2010) 0.79
Inhaled colistin for the treatment of tracheobronchitis and pneumonia in critically ill children without cystic fibrosis. Pediatr Pulmonol (2010) 0.79
Cholestasis in acute stroke: an investigation on its prevalence and etiology. Scand J Gastroenterol (2005) 0.78
High prevalence of antibody titers against Bordetella pertussis in an adult population with prolonged cough. Respir Med (2008) 0.77
Peripheral T-cell lymphoma masquerading as infectious cellulitis. Eur J Dermatol (2007) 0.77
Knowledge and practices regarding prevention of infections associated with central venous catheters: a survey of intensive care unit medical and nursing staff. Am J Infect Control (2011) 0.77
Frequency of the off-label use of monoclonal antibodies in clinical practice: a systematic review of the literature. Curr Med Res Opin (2013) 0.76
Do high doses of quinolones decrease the emergence of antibacterial resistance? A systematic review of data from comparative clinical trials. J Infect (2007) 0.76
Secular trends of blood isolates in patients from a rural area population hospitalized in a tertiary center in a small city in Greece. BMC Microbiol (2006) 0.75
Colistin in ventilator-associated pneumonia. Clin Infect Dis (2012) 0.75
Risk factors for isolation of strains susceptible only to polymyxin among patients with Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother (2006) 0.75
Henoch-Schönlein purpura associated with Proteus mirabilis urinary tract infection. J Am Acad Dermatol (2008) 0.75
Antimicrobial activity and clinical effectiveness of sisomicin: an evaluation of the literature (1995-2011). Expert Rev Anti Infect Ther (2013) 0.75
Matching criteria in case-control studies in the field of antimicrobial resistance. Microb Drug Resist (2008) 0.75
Evaluation of a direct test for seasonal influenza in outpatients. Eur J Intern Med (2010) 0.75